FMR LLC and Abigail P. Johnson filed a Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of common stock in City Therapeutics Inc. as of October 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC reported 7,025,543 shares of City Therapeutics Inc. common stock beneficially owned.
  • Percent of class: The 7,025,543 shares represent 14.0% of the outstanding common stock, according to the filing.
  • Sole voting power: FMR LLC holds sole voting power over 7,025,543 shares; shared voting power is reported as 0.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each report sole dispositive power over 7,025,543 shares, with no shared dispositive power.
  • Triggering event date: The filing identifies October 30, 2026, as the date of the event requiring this statement.
  • Third-party interest: The filing states that one or more other persons have the right to receive or direct dividends or sale proceeds from the common stock, but no single other person's interest exceeds 5% of the total outstanding shares.

FMR LLC and Abigail P. Johnson Disclose Ownership Position in City Therapeutics

According to the Schedule 13G filed November 6, 2026, FMR LLC, a Delaware-organized holding company located at 245 Summer Street, Boston, Massachusetts 02210, reported beneficial ownership of 7,025,543 shares of common stock in City Therapeutics Inc. (CUSIP: 178782108), representing 14.0% of the class. The triggering event for the filing is listed as October 30, 2026. City Therapeutics Inc. is identified in the filing as having its principal executive offices at 399 Binney St, Cambridge, MA 02141.

The filing covers two reporting persons: FMR LLC, classified as a parent holding company (type "HC"), and Abigail P. Johnson, a United States citizen classified as an individual (type "IN"). FMR LLC reports sole voting power and sole dispositive power each over 7,025,543 shares. Abigail P. Johnson reports sole dispositive power over the same 7,025,543 shares, with sole voting power listed as 0 and all shared powers listed as 0. The filing was signed by Stephanie J. Brown, acting under separate powers of attorney on behalf of both FMR LLC and Abigail P. Johnson.

The filing certifies, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." An Exhibit 99 is referenced to identify the relevant subsidiaries through which the position is held, as is standard for a parent holding company filing under Rule 13d-1(b)(1)(ii)(G).

What Was Disclosed

FMR LLC and Abigail P. Johnson disclosed a combined beneficial ownership of 7,025,543 shares of City Therapeutics Inc. common stock, equal to 14.0% of the class, in a Schedule 13G filed November 6, 2026, with an event date of October 30, 2026.